Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for ...
What is the market's perception of Repare's strategic direction and its long‑term shareholder value creation?
How does the company's updated guidance for 2025 revenue and expenses compare to prior guidance?
Are there any regulatory or clinical trial risks associated with the newly out‑licensed programs?
22 days ago